Free Float 74,50 %
Shares Float 39,84 M
Shares Outstanding 53,48 M
ALTEOGEN Inc.
Share · KR7196170005 (XKOS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ALTEOGEN Inc.
No Price
Closing Price XKOS 29.04.2026:
380.000,00 KRW
29.04.2026 06:30
Current Prices from ALTEOGEN Inc.
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
 KOSDAQ |
196170.KQ
|
KRW
|
29.04.2026 06:30
|
380.000,00 KRW
| 3.500,00 KRW
+0,93 %
|
Share Float & Liquidity
Invested Funds
The following funds have invested in ALTEOGEN Inc.:
Fund | Vol. in million 358,49 | Percentage (%) 0,20 % |
Fund | Vol. in million 1.250,27 | Percentage (%) 0,19 % |
Fund | Vol. in million 6,55 | Percentage (%) 0,04 % |
Fund | Vol. in million 6,46 | Percentage (%) 0,03 % |
Fund | Vol. in million 69,17 | Percentage (%) 0,02 % |
Company Profile for ALTEOGEN Inc. Share
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Company Data
Name ALTEOGEN Inc.
Company ALTEOGEN Inc.
Website
https://www.alteogen.com
Primary Exchange
KOSDAQ
KOSDAQ
ISIN KR7196170005
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Soon-Jae Park
Market Capitalization 20.136 Mrd.
Country South Korea
Currency KRW
Employees 0,1 T
Address 62, Yuseong-daero, 34054 Daejeon
IPO Date 2014-12-12
Dividends from 'ALTEOGEN Inc.'
| Ex-Date | Dividend per Share |
|---|---|
| 29.12.2025 | 371,00 KRW |
Stock Splits
| Date | Split |
|---|---|
| 25.10.2022 | 6:5 |
| 24.03.2021 | 5:4 |
| 23.07.2020 | 10:9 |
| 07.12.2017 | 5:9 |
Ticker Symbols
| Name | Symbol |
|---|---|
| KOSDAQ | 196170.KQ |
More Shares
Investors who hold ALTEOGEN Inc. also have the following shares in their portfolio:
